Eli Lilly’s recent stock popularity is largely driven by its obesity drug Zepbound, but the company is also expanding into genetic medicine, a promising healthcare sector. The firm has announced a collaboration and licensing deal with Seamless Therapeutics to develop treatments for hearing loss disorders. This strategic move could enhance Lilly’s market position and potentially boost its stock value. Investors are keen to see how this partnership will unfold in the evolving biotech landscape.
Loading PerspectiveSplit analysis...
